This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
by Zacks Equity Research
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
by Zacks Equity Research
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Continue to Retain Insulet Stock in Your Portfolio Now?
by Zacks Equity Research
PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.
Phibro (PAHC) Down 2.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRL Stock to Gain From the Global Biotech Incubator Program Launch
by Zacks Equity Research
Charles River's new initiative specifically caters to early-stage biotechnology developers.
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
by Zacks Equity Research
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
by Zacks Equity Research
Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
by Zacks Equity Research
ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
High Tide Inc. (HITI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
High Tide (HITI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Add Phibro Stock to Your Portfolio Right Now
by Zacks Equity Research
PAHC's Animal Health business, along with flourishing Mineral Nutrition and Performance Product businesses, sparks optimism for future growth.
Here is Why Growth Investors Should Buy Phibro (PAHC) Now
by Zacks Equity Research
Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PAHC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking for a Growth Stock? 3 Reasons Why Phibro (PAHC) is a Solid Choice
by Zacks Equity Research
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
by Zacks Equity Research
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
Investing in Phibro (PAHC)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore Phibro's (PAHC) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
by Zacks Equity Research
Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.